5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition
Gilead Sciences' (NASDAQ: GILD) executives answered several questions about its pending acquisition of Kite Pharma (NASDAQ: KITE) last week at the Citi biotech conference. However, that discussion didn't include the company's CEO, John Milligan.
Milligan and Gilead's head of hematology and oncology Alessandro Riva faced even tougher questions about the Kite deal at the Morgan Stanley healthcare conference on Monday. Here's how the big biotech's top management team responded to five key questions about the Kite buyout.
Image source: Getty Images.
Source: Fool.com
Citigroup Inc. Stock
€60.05
1.380%
The stock is one of the favorites of our community with 23 Buy predictions and 2 Sell predictions.
With a target price of 71 € there is a slightly positive potential of 18.23% for Citigroup Inc. compared to the current price of 60.05 €.
